NCT03695029 is a Phase 4 clinical trial of Tenofovir Alafenamide in Hepatitis B Virus Infection, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT03695029?

NCT03695029 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT03695029?

Interventions in NCT03695029: Tenofovir Alafenamide.

What condition does NCT03695029 study?

NCT03695029 studies Hepatitis B Virus Infection.

Is NCT03695029 still recruiting?

NCT03695029 is currently status unknown. Last updated 27 November 2020.

Last reviewed 2020-11-27 · How we verify

NCT03695029

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus

Status unknown Phase 4 Last updated 27 November 2020

What this trial tests

Phase 4 trial testing Tenofovir Alafenamide in Hepatitis B Virus Infection in 120 participants. Status unknown.

Timeline

29 December 2010

Primary endpoint
31 December 2020

31 December 2021

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	120
Start date	29 December 2010
Primary completion	31 December 2020
Estimated completion	31 December 2021
Sites	1 location across Taiwan

Drugs / interventions tested

Tenofovir Alafenamide (TENOFOVIR ALAFENAMIDE) — full drug profile →

Conditions studied

Hepatitis B Virus Infection — all drugs for Hepatitis B Virus Infection →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 40, female only, with Hepatitis B Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy of using antiviral therapy in third trimester of pregnancy to reduce mother-to-infant HBV transmission, and to access the safety of such treatment for mothers and infants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
Chen HL, Lee CN, Chang CH, Lai MW, et al · · 2024 · cited 3× · PMID 38456620 · DOI 10.1111/liv.15873

Verify or expand the search:

Other trials of Tenofovir Alafenamide

Trials testing the same drug.

NCT05467553 — A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection · Phase 2 · unknown
NCT05275023 — An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death P · Phase 2 · completed
NCT04891770 — Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of · Phase 2 · completed
NCT04674423 — The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Eleva · Phase 4 · unknown
NCT03887702 — Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therap · Phase 3 · terminated

Other recruiting trials for Hepatitis B Virus Infection

Currently open trials in the same condition.

NCT06023056 — Hepatitis B Vaccination After Neonatal Surgery · recruiting
NCT05392387 — Treatment and Prognosis of Patients With Chronic HBV Infection · recruiting
NCT07240350 — The Role and Regulatory Mechanism of Germinal Center Immune Response in Hepatitis B Virus Infection · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03695029 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 27 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03695029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing